Hypoxic-ischemic brain injury: Potential therapeutic interventions for the future

NeoReviews

Volumn 15, Issue 5, 2014, Pages

  Muller, Aaron J ^a   Marks, Jeremy D ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84899742138     PISSN: 15269906     EISSN: 15269906     Source Type: Journal    
DOI: 10.1542/neo.15-5-e177     Document Type: Article

References (85)

1. Ferriero DM. Neonatal brain injury. N Engl J Med. 2004;351 (19):1985-1995
2. Shankaran S, Laptook AR, Ehrenkranz RA, et al; National Institute of Child Health and Human Development Neonatal Research Network. Whole-body hypothermia for neonates with hypoxicischemic encephalopathy. N Engl J Med. 2005;353(15):1574-1584
3. Tagin MA, Woolcott CG, Vincer MJ, Whyte RK, Stinson DA. Hypothermia for neonatal hypoxic ischemic encephalopathy: an updated systematic review and meta-analysis. Arch Pediatr Adolesc Med. 2012;166(6):558-566
4. Simbruner G, Mittal RA, Rohlmann F, Muche R; neo. nEURO. network Trial Participants. Systemic hypothermia after neonatal encephalopathy: outcomes of neo. nEURO. network RCT. Pediatrics. 2010;126(4):e771-e778
5. Gluckman PD, Wyatt JS, Azzopardi D, et al. Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicentre randomised trial. Lancet. 2005;365(9460):663-670
6. Azzopardi DV, Strohm B, Edwards AD, et al; TOBY Study Group. Moderate hypothermia to treat perinatal asphyxial encephalopathy. N Engl J Med. 2009;361(14):1349-1358
7. Shankaran S, Pappas A, McDonald SA, et al; Eunice Kennedy Shriver NICHD Neonatal Research Network. Childhood outcomes after hypothermia for neonatal encephalopathy. N Engl J Med. 2012;366(22):2085-2092
8. Guillet R, Edwards AD, ThoresenM, et al; CoolCap Trial Group. Seven-to eight-year follow-up of the CoolCap trial of head cooling for neonatal encephalopathy. Pediatr Res. 2012;71(2):205-209
9. Sarnat HB, Sarnat MS. Neonatal encephalopathy following fetal distress. A clinical and electroencephalographic study. Arch Neurol. 1976;33(10):696-705
10. Shah PS. Hypothermia: a systematic review and meta-analysis of clinical trials. Semin Fetal Neonatal Med. 2010;15(5):238-246
11. Shankaran S, Laptook AR, Tyson JE, et al. Evolution of encephalopathy during whole body hypothermia for neonatal hypoxicischemic encephalopathy. J Pediatr. 2012;160:567-572
12. Northington FJ, Ferriero DM, Graham EM, Traystman RJ, Martin LJ. Early Neurodegeneration after Hypoxia-Ischemia in Neonatal Rat Is Necrosis while Delayed Neuronal Death Is Apoptosis. Neurobiol Dis. 2001;8(2):207-219
13. Fricker M, Tolkovsky AM. Necrosis, apoptosis, and autophagy: mechanisms of neuronal and glial cell death. Cell Culture Tech. 2011;56:305-330
14. McLean C, Ferriero D. Mechanisms of hypoxic-ischemic injury in the term infant. Semin Perinatol. 2004;28(6):425-432
15. Ankarcrona M, Dypbukt JM, Bonfoco E, et al. Glutamateinduced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. Neuron. 1995;15(4):961-973
16. Northington FJ, Chavez-Valdez R, Martin LJ. Neuronal cell death in neonatal hypoxia-ischemia. Ann Neurol. 2011;69(5):743-758
17. Abramov AY, Scorziello A, DuchenMR. Three distinct mechanisms generate oxygen free radicals in neurons and contribute to cell death during anoxia and reoxygenation. J Neurosci. 2007;27(5):1129-1138
18. Moro MA, Cárdenas A, Hurtado O, Leza JC, Lizasoain I. Role of nitric oxide after brain ischaemia. Cell Calcium. 2004;36(3-4):265-275
19. Huang Z, Huang PL, Ma J, et al. Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine. J Cereb Blood Flow Metab. 1996;16(5):981-987
20. Brown GC. Nitric oxide regulates mitochondrial respiration and cell functions by inhibiting cytochrome oxidase. FEBS Lett. 1995;369(2-3):136-139
21. Szabó C. Multiple pathways of peroxynitrite cytotoxicity. Toxicol Lett. 2003;140-141:105-112
22. Bolaños JP, Almeida A, Medina JM. Nitric oxide mediates brain mitochondrial damage during perinatal anoxia. Brain Res. 1998;787(1):117-122
23. Liu XH, Kwon D, Schielke GP, Yang GY, Silverstein FS, Barks JD. Mice deficient in interleukin-1 converting enzyme are resistant to neonatal hypoxic-ischemic brain damage. J Cereb Blood Flow Metab. 1999;19(10):1099-1108
24. McRae A, Gilland E, Bona E, Hagberg H. Microglia activation after neonatal hypoxic-ischemia. Brain Res Dev Brain Res. 1995;84 (2):245-252
25. Bona E, Andersson AL, Blomgren K, et al. Chemokine and inflammatory cell response to hypoxia-ischemia in immature rats. Pediatr Res. 1999;45(4 pt 1):500-509
26. Cowell RM, Plane JM, Silverstein FS. Complement activation contributes to hypoxic-ischemic brain injury in neonatal rats. J Neurosci. 2003;23(28):9459-9468
27. Harhausen D, Khojasteh U, Stahel PF, et al. Membrane attack complex inhibitor CD59a protects against focal cerebral ischemia in mice. J Neuroinflammation. 2010;7:15
28. Koury MJ, Bondurant MC. The mechanism of erythropoietin action. Am J Kidney Dis. 1991;18:20-23
29. Aydin A, Genç K, Akhisaroglu M, Yorukoglu K, Gokmen N, Gonullu E. Erythropoietin exerts neuroprotective effect in neonatal rat model of hypoxic-ischemic brain injury. Brain Dev. 2003;25(7): 494-498
30. Byts N, Samoylenko A, Fasshauer T, et al. Essential role for Stat5 in the neurotrophic but not in the neuroprotective effect of erythropoietin. Cell Death Differ. 2008;15(4):783-792
31. Kumral A, Genc S, Ozer E, et al. Erythropoietin downregulates bax and DP5 proapoptotic gene expression in neonatal hypoxicischemic brain injury. Biol Neonate. 2006;89(3):205-210
32. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature. 2001;412(6847):641-647
33. Juul SE, Anderson DK, Li Y, Christensen RD. Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr Res. 1998;43(1):40-49
34. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA. 2000;97(19):10526-10531
35. Zhu C, Kang W, Xu F, et al. Erythropoietin improved neurologic outcomes in newborns with hypoxic-ischemic encephalopathy. Pediatrics. 2009;124(2):e218-e226
36. Wu YW, Bauer LA, Ballard RA, et al. Erythropoietin for neuroprotection in neonatal encephalopathy: safety and pharmacokinetics. Pediatrics. 2012;130(4):683-691
37. Lynch HJ, Wurtman RJ, Moskowitz MA, Archer MC, Ho MH. Daily rhythm in human urinary melatonin. Science. 1975;187 (4172):169-171
38. Tan DX, Reiter RJ, Manchester LC, et al. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr Top Med Chem. 2002;2(2):181-197
39. Uchida K, Samejima M, Okabe A, Fukuda A. Neuroprotective effects of melatonin against anoxia/aglycemia stress, as assessed by synaptic potentials and superoxide production in rat hippocampal slices. J Pineal Res. 2004;37(4):215-222
40. Welin AK, Svedin P, Lapatto R, et al. Melatonin reduces inflammation and cell death in white matter in the mid-gestation fetal sheep following umbilical cord occlusion. Pediatr Res. 2007;61(2): 153-158
41. Lee MY, Kuan YH, Chen HY, et al. Intravenous administration of melatonin reduces the intracerebral cellular inflammatory response following transient focal cerebral ischemia in rats. J Pineal Res. 2007;42(3):297-309
42. Reiter RJ, Calvo JR, Karbownik M, Qi W, Tan DX. Melatonin and its relation to the immune system and inflammation. Ann N Y Acad Sci. 2000;917:376-386
43. Wang Z, Liu D, Zhan J, et al. Melatonin improves short and long-term neurobehavioral deficits and attenuates hippocampal impairments after hypoxia in neonatal mice. Pharmacol Res. 2013;76: 84-97
44. Hutton LC, Abbass M, Dickinson H, Ireland Z, Walker DW. Neuroprotective properties of melatonin in a model of birth asphyxia in the spiny mouse (Acomys cahirinus). Dev Neurosci. 2009;31(5): 437-451
45. Robertson NJ, Faulkner S, Fleiss B, et al. Melatonin augments hypothermic neuroprotection in a perinatal asphyxia model. Brain. 2013;136(pt 1):90-105
46. Thayyil S, ChandrasekaranM, Taylor A, et al. Cerebral magnetic resonance biomarkers in neonatal encephalopathy: a meta-analysis. Pediatrics. 2010;125(2):e382-e395
47. Fulia F, Gitto E, Cuzzocrea S, et al. Increased levels of malondialdehyde and nitrite/nitrate in the blood of asphyxiated newborns: reduction by melatonin. J Pineal Res. 2001;31(4): 343-349
48. Sadiq F. Melatonin treatment for newborn infants with moderate to severe hypoxic ischemic encephalopathy. Bethesda, MD: National Library of Medicine. Available at: http://clinicaltrials. gov/ct2/show/NCT01904786?term=NCT01904786. Accessed February 9, 2014
49. Boda M, Németh I, Boda D. The caffeine metabolic ratio as an index of xanthine oxidase activity in clinically active and silent celiac patients. J Pediatr Gastroenterol Nutr. 1999;29(5):546-550
50. Kaandorp JJ, Derks JB, Oudijk MA, et al. Antenatal allopurinol reduces hippocampal brain damage after acute birth asphyxia in late gestation fetal sheep. Reprod Sci. 2014;21(2):251-259
51. Karageorgos N, Patsoukis N, Chroni E, Konstantinou D, Assimakopoulos SF, Georgiou C. Effect of N-acetylcysteine, allopurinol and vitamin E on jaundice-induced brain oxidative stress in rats. Brain Res. 2006;1111(1):203-212
52. Yonden Z, Aydin M, Kilbas A, Demirin H, Sutcu R, Delibas N. Effects of ammonia and allopurinol on rat hippocampal NMDA receptors. Cell Biochem Funct. 2010;28(2):159-163
53. Pacher P, Nivorozhkin A, Szabó C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006;58(1):87-114
54. Benders MJ, Bos AF, Rademaker CM, et al. Early postnatal allopurinol does not improve short term outcome after severe birth asphyxia. Arch Dis Child Fetal Neonatal Ed. 2006;91(3):F163-F165
55. Gunes T, Ozturk MA, Koklu E, Kose K, Gunes I. Effect of allopurinol supplementation on nitric oxide levels in asphyxiated newborns. Pediatr Neurol. 2007;36(1):17-24
56. Masaoka N, Nakajima Y, Hayakawa Y, et al. Transplacental effects of allopurinol on suppression of oxygen free radical production in chronically instrumented fetal lamb brains during intermittent umbilical cord occlusion. J Matern Fetal Neonatal Med. 2005;18(1):1-7
57. van Bel F, Benders M, Derks J, et al. Antenatal allopurinol during fetal hypoxia. Bethesda, MD: National Library of Medicine. Available at: http://clinicaltrials.gov/ct2/show/NCT00189007? term=NCT00189007. Accessed February 9, 2014
58. Follett PL, Deng W, Dai W, et al. Glutamate receptormediated oligodendrocyte toxicity in periventricular leukomalacia: a protective role for topiramate. J Neurosci. 2004;24(18):4412-4420
59. Noh MR, Kim SK, Sun W, et al. Neuroprotective effect of topiramate on hypoxic ischemic brain injury in neonatal rats. Exp Neurol. 2006;201(2):470-478
60. Schubert S, Brandl U, Brodhun M, et al. Neuroprotective effects of topiramate after hypoxia-ischemia in newborn piglets. Brain Res. 2005;1058(1-2):129-136
61. Liu Y, Barks JD, Xu G, Silverstein FS. Topiramate extends the therapeutic window for hypothermia-mediated neuroprotection after stroke in neonatal rats. Stroke. 2004;35(6):1460-1465
62. Filippi L, Poggi C, la Marca G, et al. Oral topiramate in neonates with hypoxic ischemic encephalopathy treated with hypothermia: a safety study. J Pediatr. 2010;157(3):361-366
63. Griffin IJ. Topiramate in neonates receiving whole body cooling for hypoxic ischemic encephalopathy. Bethesda, MD: National Library of Medicine. Available at: http://clinicaltrials.gov/ct2/show/ NCT01765218?term=NCT01765218. Accessed February 9, 2014
64. Filippi L. Safety and efficacy of topiramate in neonates with hypoxic ischemic encephalopathy treated with hypothermia (NeoNATI). Bethesda, MD: National Library of Medicine. Available at: http:// clinicaltrials.gov/ct2/show/NCT01241019?term=NCT01241019. Accessed February 9, 2014
65. Baumert JH, Hein M, Hecker KE, Satlow S, Schnoor J, Rossaint R. Autonomic cardiac control with xenon anaesthesia in patients at cardiovascular risk. Br J Anaesth. 2007;98(6):722-727
66. Wappler F, Rossaint R, Baumert J, et al; Xenon Multicenter Study Research Group. Multicenter randomized comparison of xenon and isoflurane on left ventricular function in patients undergoing elective surgery. Anesthesiology. 2007;106(3):463-471
67. Banks P, Franks NP, Dickinson R. Competitive inhibition at the glycine site of the N-methyl-D-aspartate receptor mediates xenon neuroprotection against hypoxia-ischemia. Anesthesiology. 2010;112(3):614-622
68. Wilhelm S, Ma D, Maze M, Franks NP. Effects of xenon on in vitro and in vivo models of neuronal injury. Anesthesiology. 2002; 96(6):1485-1491
69. Hobbs C, Thoresen M, Tucker A, Aquilina K, Chakkarapani E, Dingley J. Xenon and hypothermia combine additively, offering long-term functional and histopathologic neuroprotection after neonatal hypoxia/ischemia. Stroke. 2008;39(4):1307-1313
70. Chakkarapani E, Dingley J, Liu X, et al. Xenon enhances hypothermic neuroprotection in asphyxiated newborn pigs. Ann Neurol. 2010;68(3):330-341
71. Rao S, Lin Z, Drobyshevsky A, et al. Involvement of neuronal nitric oxide synthase in ongoing fetal brain injury following near-term rabbit hypoxia-ischemia. Dev Neurosci. 2011;33(3-4):288-298
72. Thoresen M, Liu X, Tooley J, et al. First human use of 50% xenon inhalation during hypothermia for neonatal hypoxic ischemic encephalopathy: the "Coolxenon" Feasibility Study. Pediatric Academic Societies. 2011:ePAS20111660.7
73. Azzopardi D. Neuroprotective effects of hypothermia combined with inhaled xenon following perinatal asphyxia (TOBYXe). Bethesda, MD: National Library of Medicine. Available at: http:// clinicaltrials.gov/ct2/show/NCT00934700. Accessed February 9, 2014
74. Thoresen M. Xenon and cooling therapy in babies at high risk of brain injury following poor condition at birth (CoolXenon2). Bethesda, MD: National Library of Medicine. Available at: http:// clinicaltrials.gov/ct2/show/NCT01545271. Accessed February 9, 2014
75. Dalkara T, Yoshida T, Irikura K, Moskowitz MA. Dual role of nitric oxide in focal cerebral ischemia. Neuropharmacology. 1994;33 (11):1447-1452
76. Drury PP, Davidson JO, van den Heuij LG, et al. Partial neuroprotection by nNOS inhibition during profound asphyxia in preterm fetal sheep. Exp Neurol. 2013;250:282-292
77. Yu L, Derrick M, Ji H, et al. Neuronal nitric oxide synthase inhibition prevents cerebral palsy following hypoxia-ischemia in fetal rabbits: comparison between JI-8 and 7-nitroindazole. Dev Neurosci. 2011;33(3-4):312-319
78. Grimm S. The ER-mitochondria interface: the social network of cell death. Biochim Biophys Acta. 2012;1823:327-334
79. Wu G, Majewski J, Ege C, Kjaer K, Weygand MJ, Lee KY. Interaction between lipid monolayers and poloxamer 188: an X-ray reflectivity and diffraction study. Biophys J. 2005;89(5): 3159-3173
80. Firestone MA, Seifert S. Interaction of nonionic PEO-PPO diblock copolymers with lipid bilayers. Biomacromolecules. 2005;6 (5):2678-2687
81. Shelat PB, Plant LD, Wang JC, Lee E, Marks JD. The membrane-active tri-block copolymer pluronic F-68 profoundly rescues rat hippocampal neurons from oxygen-glucose deprivationinduced death through early inhibition of apoptosis. J Neurosci. 2013;33(30):12287-12299
82. Marks JD, Pan CY, Bushell T, et al. Amphiphilic, tri-block copolymers provide potent, membrane-targeted neuroprotection. FASEB J. 2001;15:1107-1109
83. Marks JD, Doi A, Garcia AG, et al. Poloxamer 188, an amphiphilic tri-block co-polymer, provides profound hippocampal neuroprotection following transient global forebrain ischemia in the Mongolian gerbil. 2007 Neuroscience Meeting Planner San Diego, CA, Nov. 3-7, 2007
84. Ballas SK, Files B, Luchtman-Jones L, et al. Safety of purified poloxamer 188 in sickle cell disease: phase I study of a non-ionic surfactant in the management of acute chest syndrome. Hemoglobin. 2004;28(2):85-102
85. Duvinage C, Millecamps S, Sagnier A, et al. One-month intravenous toxicity studies of poloxamer 188 in male Sprague-Dawley rats and in beagle dogs. Toxicol Lett. 1996;88(suppl 1):101